Epicrispr, Infinimmune snag combined $165M in VC cash
Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
Read the full article on the original site.
Read Full Article